Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation

• DOI: 10.1007/s10792-012-9562-0
• Publication Date: 2012-04-17T11:51:41Z
• Authors: Katerina Hufendiek; Karsten Hufendiek; Georgios Panagakis; Horst Helbig; Maria-Andreea Gam...
• Keywords: Aged, 80 and over; Indocyanine Green; Male; Angiogenesis Inhibitors; Exudates and Transudates; Middle Aged; Retinal Neovascularization; Antibodies, Monoclonal, Humanized; Retina; 3. Good health; Bevacizumab; Macular Degeneration; 03 medical and health sciences; 0302 clinical medicine; Ranibizumab; Intravitreal Injections; Retreatment; Humans; Female; Fluorescein Angiography; Tomography, Optical Coherence; Aged; Retrospective Studies

Retinal angiomatous proliferation (RAP) is a variant of exudative age-related macular degeneration with particularly bad prognosis. The purpose of this work is to describe the long-term functional and morphological outcome of patients treated with intravitreal bevacizumab and ranibizumab. Retrospective case series of 16 eyes treated with bevacizumab and 19 eyes treated with ranibizumab. All patients received initially three intravitreal injections of bevacizumab (1.25 mg/0.05 ml) or ranibizumab (0.5 mg/0.05 ml) every 4 weeks. Follow-up ranged from 1 to 7 months after the third injection. Complete ophthalmologic examination including best-corrected visual acuity (VA), optical coherence tomography, fluorescein angiography, and in selected cases, indocyanine green angiography was performed. Triple intravitreal injections resulted in improvement of VA in bevacizumab-treated as well as in ranibizumab-treated patients; logarithm of the minimal angle of resolution (logMAR) 0.84 before treatment and 0.67 at month 9, and logMAR 0.75 before treatment and 0.59 at month 9, respectively. Central macular thickness (CMT) in the bevacizumab group improved from 363.67 ± 47.4 μm at baseline to 328 ± 49.77 μm at month 6 (p = 0.03) and 301 ± 129.69 at month 9 (p = 0.35). CMT in the ranibizumab group improved from 545.62 ± 167.39 μm at baseline to 395.88 ± 169.37 μm at month 6 and 411.83 ± 212.41 μm at month 9 (p = 0.03, p = 0.05, respectively). Patients with RAP might benefit from both intravitreal bevacizumab and ranibizumab treatments with stabilization of VA over a longer period of time. Close follow-up should nevertheless be performed in this special subgroup because of the high recurrence rate.